

Gastrointestinal Immune-Related Adverse Event Management Algorithm

Grading of diarrhoea	Action	Follow up
<p style="text-align: center;">Grade 1</p> <p>Increase of <4 stools per day Mild increase in ostomy output compared to baseline Clinically well with normal vital signs</p>	<p>Investigations</p> <ul style="list-style-type: none"> Baseline bloods: FBC, CRP, U&E, LFTs, full TFTs, cortisol Faecal calprotectin Stool culture including C.difficile <p>Management</p> <ul style="list-style-type: none"> Continue ICI therapy Low fibre diet, spasmolytic 	<p>If remains stable / resolves:</p> <ul style="list-style-type: none"> Early review within 1-2 weeks Monitor closely and advise patient to report worsening symptoms immediately Ensure patient is completing stool diary <p>If worsens / persists >15 days or deranged U+Es:</p> <ul style="list-style-type: none"> Treat as G2 or 3/4
<p style="text-align: center;">Grade 2</p> <p>4-6 stools per day over baseline / moderate increase in ostomy output compared to baseline</p>	<p>Investigations</p> <ul style="list-style-type: none"> As per G1 Stool chart, faecal elastase Whole blood PCR CMV Consider viral pathogen screen e.g. Norovirus Flexible sigmoidoscopy ^a <p>Management</p> <ul style="list-style-type: none"> Hold I-O therapy Start oral prednisolone 1mg/kg/day (maximum 60mg OD) PPI cover 	<p>Review in 1 week.</p> <p>If improves to G1:</p> <ul style="list-style-type: none"> Taper oral steroids over 8 weeks (see separate steroid-weaning document) Resume I-O therapy <p>If worsens or persists more than 5-7 days with steroids:</p> <ul style="list-style-type: none"> Treat as G3/4
<p style="text-align: center;">Grade 3 – 4</p> <p>7 or more stools per day over baseline / severe increase in ostomy output Severe or continuous abdominal pain Fever 37.8oC Tachycardia over 90bpm Dehydration</p> <p><u>Consider:</u> Rising CRP or CRP over 30 if previously normal Falling Hb or Hb less than 105g/L if previously normal Falling albumin or low albumin if previously normal</p>	<p>Investigations</p> <ul style="list-style-type: none"> As per G2 Pre-biologics screen AXR CTAP if persistent pain, peritonitic or febrile <p>Management</p> <ul style="list-style-type: none"> Discontinue I-O therapy Admit patient 1mg/kg/day IV Methylprednisolone OD (+ PPI) IV fluid replacement Daily U&Es with fluid balance chart Continue accurate stool chart Refer to gastroenterology 	<p>If symptoms resolving:</p> <ul style="list-style-type: none"> Continue IV for at least 3-5 days then switch to PO prednisolone 1mg/kg OD (maximum 60mg OD) and taper as per standard regimen <p>If symptoms persist more than 3-5 days or recur after improvement:</p> <ul style="list-style-type: none"> Refer to gastroenterology for ongoing guidance Add infliximab (5mg/kg if no contraindication) workup on next page <p>If persists more than 3-5 days or worsens after infliximab:</p> <ul style="list-style-type: none"> Consider switching to other biologics guided by gastroenterology ^b Consider early transfer to gastroenterology ward 7F ^c Refer to surgeons for consideration of colectomy

Additional information:

- Any patient with I-O colitis should NOT be commenced on Loperamide. This will mask the symptoms of colitis without addressing the underlying cause.
- ^a If biopsies from endoscopy show microscopic colitis, switch steroids to Budesonide 9mg OD for 6 weeks, then reduce to 6mg OD for one week, then to 3mg OD for another week then stop.
- ^b E.g. high dose infliximab, ustekinumab, tofacitinib, faecal microbiota transplantation, extracorporeal photopheresis.
- ^c Consider early transfer of IO colitis inpatients refractory to infliximab and/ or vedolizumab to the gastroenterology ward 7F if not improving in 48-72hrs after dose through consultant to consultant discussion. Once transferred, acute oncology service can consult at JRH.
- Infliximab Workup: to include- TB Quantiferon test, hepatitis screen, HIV, varicella zoster antibodies (IGG antibody), chest X-Ray (if chest CT not already performed)

Issue date:	08.01.2025
Version No:	2.0
Authors:	Anil Babar Alekhia Nippani Vincent Cheung